OncologyCE
LECTURECME

Expert Connect: Insights Into the Management of Treatment-Experienced Patients With SCLC

Author(s)/Faculty: Jacob Sands, MD
Release Date: 12/21/2020Expiration Date: 12/20/2021
Credit Type: CMENumber of Credits: 0.5
Content Type: LectureProvider:
Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancers and is usually more aggressive than non-small cell lung cancer (NSCLC). Until recently, few treatment options were available for SCLC, but recent approvals in the first- and second-line settings have advanced progression-free as well as overall survival in these patients. Unfortunately, while most patients with SCLC respond initially to first-line chemotherapy, almost all tumors recur, but response rates in the second-line setting are significantly lower. Within this CME activity, Dr. Jacob Sands evaluates the latest clinical evidence regarding the use of new and emerging options for the management of patients with SCLC who have progressed on first-line therapies as well as examines how these therapeutic options may address challenges and unmet needs in this patient population.